Medical Cannabis and the Misuse of Drugs Act 1971

The Legal Framework for Controlled Substances in the UK

• The Misuse of Drugs Act 1971 classifies cannabis as a Class B controlled substance
• Schedule 1 of the Misuse of Drugs Regulations 2001 originally prohibited all medical use
• The 2018 rescheduling moved specified cannabis-based medicines to Schedule 2
• Unlicensed cannabis products remain Schedule 1 and cannot be legally prescribed

The Misuse of Drugs Act 1971 remains the cornerstone of drug control legislation in the United Kingdom. For medical cannabis, understanding the interaction between the Act itself and the subordinate Misuse of Drugs Regulations is essential for any clinician, pharmacist, or importer operating in the licensed supply chain.

What Schedule 2 Classification Means in Practice

• Schedule 2 drugs can be prescribed by registered medical practitioners
• Controlled drug registers must record all receipts and supplies
• Safe custody requirements apply to Schedule 2 medicines in pharmacy settings
• Prescriptions must comply with CD prescription requirements under the Regulations

The practical implications of Schedule 2 classification extend across the entire supply chain. Importers, wholesalers, and dispensing pharmacies must each hold appropriate Home Office licences and maintain records that can withstand regulatory scrutiny.

Home Office Licensing Requirements

• Importers require a specific controlled drug import licence for each consignment
• Wholesale dealers distributing Schedule 2 cannabis medicines need a Controlled Drugs licence
• Pharmacies must hold a Retail Pharmacy licence and register with the GPhC
• Any change in product, origin, or quantity typically requires a new or amended licence

The Home Office Drugs and Firearms Licensing Unit administers controlled drug licences in England, Scotland, and Wales. Applications require detailed information about the product, supplier, storage arrangements, and responsible individuals. Lead times of several weeks are standard and should be factored into commercial planning.

Consequences of Non-Compliance

• Unlicensed supply of Schedule 2 drugs carries significant criminal penalties under the Act
• Clinicians can face GMC fitness-to-practise proceedings for improper prescribing
• Pharmacies risk GPhC regulatory action and licence revocation
• Corporate liability extends to directors and officers under the Act

Compliance with the Misuse of Drugs Act is non-negotiable for any legitimate medical cannabis business in the UK. The regulatory risk of operating outside licensed parameters is severe, and the reputational damage to the broader medical cannabis sector from enforcement actions can set the industry back significantly.